For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 5,232,541 | 8,449,085.5* | 4,968,596 | 4,926,936 |
| Acquisition-related costs (note 5) | - | 919,904.5* | - | - |
| General and administrative expenses | 2,297,358 | -2,481,389.5* | 1,761,007 | 4,949,020 |
| Operating loss | 7,529,899 | 6,887,600.5* | 6,729,603 | 9,875,956 |
| Employee retention tax credit | - | 28,393.5* | - | - |
| Grant income | - | 22,077* | 138,299 | 322,655 |
| Interest expense | 27,974 | 575,687* | 16,532 | - |
| Interest income | 21,275 | 82,944* | 6,060 | 29,466 |
| Other expense | - | - | 185,019 | - |
| Change in fair value of kineta merger holdback shares | - | 2,263,585.75* | -315,660 | - |
| Loss on kineta employee separation payments assumed from merger | - | 46,254.75* | - | - |
| Total other (expense) income | -6,699 | 1,775,058.5* | -372,852 | 352,121 |
| Net loss | -7,536,598 | -5,112,542* | -7,102,455 | -9,523,835 |
| Series a preferred cash dividend | 2,089 | 2,089* | 2,089 | 2,089 |
| Deemed dividend on warrant modifications | - | 0* | - | - |
| Net loss attributable to common stockholders | -7,538,687 | -5,114,631 | -7,104,544 | -9,525,924 |
| Basic EPS | -0.13 | -0.105 | -0.14 | -0.21 |
| Diluted EPS | -0.13 | -0.105 | -0.14 | -0.21 |
| Basic Average Shares | 60,010,237 | 48,560,063 | 50,666,430 | 44,555,095 |
| Diluted Average Shares | 60,010,237 | 48,560,063 | 50,666,430 | 44,555,095 |
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)